Key result
Cyclophilin A inhibits human respiratory syncytial virus (RSV) replication by binding to RSV-N and weakening its interaction with RSV-P, leading to decreased viral production.
Cyclophilin A inhibits RSV replication by binding to the viral capsid protein RSV-N, offering a potential target for new antiviral drugs.
May identify cyclophilin A as RSV antiviral target; hypothesis-generating and leaves open translation to human therapy.
RSV-N, packed in the viral genome to form the ribonucleoprotein (RNP) complex, which is recognized by the RSV RNA-dependent RNA polymerase (RdRp) complex to initiate viral replication and transcription, plays an indispensable role in the viral biosynthesis process. cypA, binding to RSV-N, may impair this function by weakening the interaction between RSV-N and RSV-P, thus leading to decreased viral production. Our research provides novel insight into cypA antiviral function, including binding to viral capsid protein to inhibit viral replication, which may be helpful for new antiviral drug exploration.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2021) studied Human Respiratory Syncytial Virus (RSV). Cyclophilin A (cypA) was evaluated on Viral replication and production. Cyclophilin A inhibits human respiratory syncytial virus (RSV) replication by binding to RSV-N and weakening its interaction with RSV-P, leading to decreased viral production.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: